Sanofi halted its Phase 3 MOBILIZE study of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring board concluded the trial was unlikely to achieve sufficient efficacy. Sanofi said there were no safety concerns, but the interim analysis failed to support continued development. The setback adds pressure to Sanofi’s broader pipeline efforts, coming after multiple R&D disappointments and as competition grows for therapies aimed at complement pathways in CIDP. Analyst commentary in the report pointed to downstream implications for similarly positioned developers, including Dianthus Therapeutics. Sanofi said it is assessing the program’s future and whether to continue another Phase 3 study, VITALIZE, which compares riliprubart with IVIg. The decision reflects how early interim futility determinations are increasingly shaping late-stage oncology and neurology development risk profiles.